Open AccessPlasma Levels of Atazanavir and the Risk of Hyperbilirubinemia Are Predicted by the 3435C->T Polymorphism at the Multidrug Resistance Gene 1
Author(s) -
Sonia RodríguezNóvoa,
Pablo Barreiro,
A. Rendon,
A. Barrios,
Angélica Corral,
Inmaculada Jiménez-Nàcher,
J. Gonzalez-Lahoz,
Vincent Soriano
Publication year - 2005
Publication title -
clinical infectious diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.44
H-Index - 336
eISSN - 1537-6591
pISSN - 1058-4838
DOI - 10.1086/499056
Subject(s) - atazanavir , genotype , medicine , multiple drug resistance , virology , human immunodeficiency virus (hiv) , gene polymorphism , gene , pharmacology , drug resistance , antiretroviral therapy , genetics , biology , viral load
The 3435C-->T polymorphism at the multidrug resistance gene 1 (MDR1) was examined in 74 patients with human immunodeficiency virus who initiated atazanavir therapy. The MDR1 genotype distribution at position 3435 was 28% CC, 45% CT, and 27% TT. Plasma levels of atazanavir were significantly higher in patients with genotype CC than in those with CT or TT, and bilirubin levels correlated with atazanavir concentrations.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom